EUCTR2019-002587-28-NL进行中（未招募）1 期
ABSORB 2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome. - ABSORB_2: Oral antibiotic drug absorption in patients with short bowel syndrome
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Radboudumc
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patients with current use of long-term home parenteral nutrition (> 3 consecutive months) and clinically stable
- •-Diagnosed with SBS (total small bowel length 200cm or less after Treitz ligamentum)
- •-Age 18 years of older
- •-Signed Informed Consent
- •-Patient is fully able to understand the nature of the proposed intervention.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •-Active vomiting, worsening or new diarrhea
- •-Contra-indications (for example allergies or interfering co-medication) for any of the study treatments
- •-Impaired renal function (creatinin clearance <30ml/min/1,73m2)
- •-Pregnancy
- •-Morbid obesity (BMI >35)
- •-Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator
研究者
相似试验
已完成
不适用
ABSORB-2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome.short bowel syndromeNL-OMON48315Radboud Universitair Medisch Centrum18
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatmentewly diagnosed multiple myelomaMedDRA version: 14.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2013-003113-17-GRMillennium Pharmaceuticals, Inc.70
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment, and in patients with multiple myeloma whose disease is no longer responding or has not responded to previous treatmentEUCTR2013-003113-17-SEMillennium Pharmaceuticals, Inc.148
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination ofcyclophosphamide and dexamethasone improves the response to therapyin patients who have been newly diagnosed with multiple myeloma andhave not received previous anti-myeloma treatment, and in patients withmultiple myeloma whose disease is no longer responding or has notresponded to previous treatmentewly diagnosed multiple myelom and relapsed and/or refractorymultiple myelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2013-003113-17-PLMillennium Pharmaceuticals, Inc.148
招募中
Unknown
Observational Study on the Development of an Oral Condition Assessment SystemPeriodontal DiseaseJPRN-UMIN000053610Sunstar Inc.400